Published in Ann Oncol on May 19, 2005
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | NCT00514046
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol (2009) 1.80
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2010) 1.59
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer (2003) 1.40
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol (2010) 1.27
ZD6474--clinical experience to date. Br J Cancer (2005) 1.23
The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med (2012) 1.21
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol (2012) 1.15
Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer (2004) 1.15
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One (2009) 1.13
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics (2010) 1.13
What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol (2008) 1.13
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer (2009) 1.08
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol (2010) 1.06
Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol (2009) 1.04
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res (2013) 1.03
Present and future evolution of advanced breast cancer therapy. Breast Cancer Res (2010) 1.01
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist (2013) 0.99
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2010) 0.98
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer (2011) 0.97
Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist (2011) 0.96
Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management. AAPS J (2006) 0.95
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer (2007) 0.94
Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol (2010) 0.94
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145. Invest New Drugs (2006) 0.93
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis (2011) 0.91
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs (2010) 0.90
Role of vandetanib in the management of medullary thyroid cancer. Biologics (2012) 0.88
Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol (2009) 0.85
Multi-targeted approach in the treatment of thyroid cancer. Ther Clin Risk Manag (2008) 0.85
Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel. Ann Dermatol (2011) 0.85
Long-term High Salt Diet Causes Hypertension and Decreases Renal Expression of Vascular Endothelial Growth Factor in Sprague-Dawley Rats. J Am Soc Hypertens (2010) 0.85
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D (2011) 0.85
Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 0.84
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget (2010) 0.84
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res (2015) 0.83
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs (2008) 0.83
Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer. Clin Med Insights Oncol (2011) 0.82
Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol (2014) 0.82
Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res (2011) 0.81
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head Neck (2012) 0.80
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol (2012) 0.80
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents. Invest New Drugs (2010) 0.80
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs (2011) 0.79
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. Onco Targets Ther (2011) 0.78
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Invest New Drugs (2013) 0.78
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.78
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther (2008) 0.78
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol (2006) 0.77
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. Ther Clin Risk Manag (2011) 0.77
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol (2014) 0.76
Impaired Neovascularization and Reduced Capillary Supply in the Malignant vs. Non-malignant Course of Experimental Renovascular Hypertension. Front Physiol (2016) 0.75
Predicting success in regulatory approval from Phase I results. Cancer Chemother Pharmacol (2014) 0.75
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol (2016) 0.75
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs (2015) 0.75
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Vandetanib in advanced non small cell lung cancer: a promise unfulfilled. Transl Lung Cancer Res (2013) 0.75
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. Eur Thyroid J (2016) 0.75
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther (2017) 0.75
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clin Pharmacol Ther (2017) 0.75
Adenovirus DNA. I. Molecular weight and conformation. Proc Natl Acad Sci U S A (1967) 5.55
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
An adenovirus E1a protein region required for transformation and transcriptional repression. Cell (1986) 4.56
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med (2000) 4.27
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Risk of lung cancer associated with residential radon exposure in south-west England: a case-control study. Br J Cancer (1998) 4.24
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Functional domains of adenovirus type 5 E1a proteins. Cell (1987) 3.79
A single subunit from avian myeloblastosis virus with both RNA-directed DNA polymerase and ribonuclease H activity. Proc Natl Acad Sci U S A (1973) 3.71
Oncogenic viruses. Annu Rev Biochem (1970) 3.65
Vancomycin susceptibility and identification of motile enterococci. J Clin Microbiol (1991) 3.61
Biochemical studies on adenovirus multiplication. 18. Resolution of early virus-specific RNA species in Ad 2 infected and transformed cells. Virology (1971) 3.54
Mechanism of carcinogenesis by RNA tumor viruses. I. An RNA-dependent DNA polymerase in murine sarcoma viruses. Proc Natl Acad Sci U S A (1970) 3.47
Occupational asthma in an electronics factory. Thorax (1979) 3.03
Biochemical studies on adenovirus multiplication, XIX. Resolution of late viral RNA species in the nucleus and cytoplasm. Proc Natl Acad Sci U S A (1971) 3.02
Immunological identification of two adenovirus 2-induced early proteins possibly involved in cell transformation. Nature (1976) 3.01
Isolation of a human papillomavirus from a patient with epidermodysplasia verruciformis: presence of related viral DNA genomes in human urogenital tumors. Proc Natl Acad Sci U S A (1982) 2.90
Immunoautoradiographic detection of proteins after electrophoretic transfer from gels to diazo-paper: analysis of adenovirus encoded proteins. Proc Natl Acad Sci U S A (1981) 2.88
Multiple functional domains of human transcription factor IIB: distinct interactions with two general transcription factors and RNA polymerase II. Genes Dev (1993) 2.87
The maximal sniff in the assessment of diaphragm function in man. Clin Sci (Lond) (1985) 2.83
Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA (1990) 2.82
Biochemical studies on adenovirus multiplication. IX. Chemical and base composition analysis of 28 human adenoviruses. Proc Natl Acad Sci U S A (1965) 2.79
DNA hybridization and contour-clamped homogeneous electric field electrophoresis for identification of enterococci to the species level. J Clin Microbiol (1995) 2.69
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol (2010) 2.64
Young people, alcohol, and designer drinks: quantitative and qualitative study. BMJ (1997) 2.64
Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol (1993) 2.59
The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics (1997) 2.55
Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum (1998) 2.51
Measurement of twitch transdiaphragmatic, esophageal, and endotracheal tube pressure with bilateral anterolateral magnetic phrenic nerve stimulation in patients in the intensive care unit. Crit Care Med (2001) 2.47
Viral RNA subunits in cells transformed by RNA tumor viruses. Science (1972) 2.44
The effects of ventilation of dogs with different gas mixtures on airway calibre and lung mechanics. J Physiol (1966) 2.42
Carrying large fuel loads during sustained bird flight is cheaper than expected. Nature (2001) 2.41
Mechanism of carcinogenesis by RNA tumor viruses. 3. Formation of RNA, DNA complex and duplex DNA molecules by the DNA polymerase (s) of avian myeloblastosis virus. Proc Natl Acad Sci U S A (1970) 2.37
Cell-free translation of immunoglobulin messenger RNA from MOPC-315 plasmacytoma and MOPC-315 NR, a variant synthesizing only light chain. Proc Natl Acad Sci U S A (1975) 2.37
Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol (1997) 2.32
Reduction of transmission of shigellosis by control of houseflies (Musca domestica) Lancet (1991) 2.30
Triggered correlation. IEEE Trans Biomed Eng (1968) 2.30
Improved survival for patients with acute myelogenous leukemia. J Clin Oncol (1995) 2.30
Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer (1996) 2.30
Work-related respiratory disease in employees leaving an electronics factory. Thorax (1979) 2.29
Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet (1988) 2.28
Formation of viral RNA-DNA hybrid molecules by the DNA polymerase of sarcoma-leukaemia viruses. Nature (1970) 2.27
Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (2001) 2.24
The genome of RNA tumor viruses contains polyadenylic acid sequences. Proc Natl Acad Sci U S A (1972) 2.23
Virus specific RNA in cells transformed by RNA tumour viruses. Nat New Biol (1971) 2.22
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
The mechanism of viral carcinogenesis by DNA mammalian viruses: viral-specific RNA in polyribosomes of adenovirus tumor and transformed cells. Proc Natl Acad Sci U S A (1966) 2.19
Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield. Transfusion (1997) 2.17
Mechanism of viral carcinogenesis by DNA mammalian viruses. VII. Viral genes transcribed in adenovirus type 2 infected and transformed cells. Proc Natl Acad Sci U S A (1970) 2.17
A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol (1995) 2.16
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol (2012) 2.16
Biochemical studies on adenovirus multiplication. XII. Plaquing efficiencies of purified human adenoviruses. Virology (1967) 2.16
Cell-binding domain of adenovirus serotype 2 fiber. J Virol (1994) 2.16
Thirty-one human adenovirus serotypes (Ad1-Ad31) form five groups (A-E) based upon DNA genome homologies. Virology (1979) 2.14
Effects of temperature on Vitalograph spirometer readings. Thorax (1983) 2.13
Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12
Physicochemical characterization of adeno-associated satellite virus type 4 and its nucleic acid. J Virol (1967) 2.10
The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis. Infect Immun (2000) 2.10
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol (1992) 2.10
RNA-directed DNA polymerase--properties and functions in oncogenic RNA viruses and cells. Prog Nucleic Acid Res Mol Biol (1974) 2.10
Molecular interactions of ribosomal components. I. Identification of RNA binding sites for individual 30S ribosomal proteins. Mol Gen Genet (1970) 2.09
ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J Biol Chem (1987) 2.09
Trust and confidence: towards mutual acceptance of ethics committee approval of multicentre studies. Intern Med J (2004) 2.07
Human adenoviruses: growth, purification, and transfection assay. Methods Enzymol (1979) 2.06
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05
Preparation and characterization of highly radioactive in vitro labeled adenovirus DNA and DNA restriction fragments. Biochemistry (1977) 2.04
Variability of maximum expiratory flow-volume curves. J Appl Physiol (1974) 2.03
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol (2001) 2.01
Sequence relatedness between the subunits of avian myeloblastosis virus reverse transcriptase. J Biol Chem (1975) 2.01
Local perspective on a rare brain tumour: adult medulloblastoma. Intern Med J (2013) 1.97
Assessment of established cases of chronic simple glaucoma. Br J Ophthalmol (1970) 1.94
Biochemical studies on adenovirus multiplication. XV. Transcription of the adenovirus type II genome during productive infection. Virology (1969) 1.94
Migration along orthodromic sun compass routes by arctic birds. Science (2001) 1.92
Genetic and phenotypic analysis of Borrelia valaisiana sp. nov. (Borrelia genomic groups VS116 and M19). Int J Syst Bacteriol (1997) 1.92
Molecular interactions of ribosomal components. II. Site-specific complex formation between 30S proteins and ribosomal RNA. Mol Gen Genet (1971) 1.91
Assessment of diaphragm weakness. Am Rev Respir Dis (1988) 1.90
The stress response in Chinese hamster ovary cells. Regulation of ERp72 and protein disulfide isomerase expression and secretion. J Biol Chem (1990) 1.89
Fall in vital capacity with posture. Br J Dis Chest (1985) 1.89
Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine (2001) 1.86
An anatomical explanation for good-prognosis rheumatoid arthritis. Lancet (1999) 1.84
Indole-3-Acetic Acid and Flowering. Science (1948) 1.84
Ribonuclease H: a ubiquitous activity in virions of ribonucleic acid tumor viruses. J Virol (1972) 1.84
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation (2001) 1.83
Identification of families of overlapping polypeptides coded by early "transforming" gene region 1 of human adenovirus type 2. Virology (1979) 1.83
ERp72, an abundant luminal endoplasmic reticulum protein, contains three copies of the active site sequences of protein disulfide isomerase. J Biol Chem (1990) 1.83
Inhibitors of the RNA and DNA dependent polymerase activities of RNA tumour viruses. Nat New Biol (1971) 1.80
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer (2007) 1.79
Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol (2001) 1.79
Genome size and complexity in Azotobacter chroococcum. J Gen Microbiol (1984) 1.79
The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum (1999) 1.78
Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77
Occupational asthma in an electronics factory: a case control study to evaluate aetiological factors. Thorax (1979) 1.77
Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging (2011) 1.76
Biochemical studies on adenovirus multiplication. XIV. Macromolecule and enzyme synthesis in cells replicating oncogenic and nononcogenic human adenovirus. Virology (1969) 1.75
Different mode of action of ribonuclease H in purified alpha and alpha beta ribonucleic acid-directed deoxyribonucleic acid polymerase from avian myeloblastosis virus. J Biol Chem (1974) 1.74
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 1.73
A brave new world of cancer screening. Aust N Z J Med (1994) 1.71
Isolation of DNA Strand-specific early messenger RNA species in cells infected by human adenovirus 2. Proc Natl Acad Sci U S A (1974) 1.71